I found a recent(2017) article in regards to NHS76( Selectine IL-12 ) the humanized form of T.N.T. combined with a PD-L1 agent. I do not know if we still own the rights to NHS76 , but if we do Dr. Lias should be made aware of the potential of the T.N.T. platform.
NCBINCBI Logo
Skip to main content
Skip to navigation
Resources
How To
About NCBI Accesskeys
Sign in to NCBI
PubMed
US National Library of Medicine National Institutes of Health
Search databaseSearch term
Search
AdvancedHelp
Result Filters
Format: AbstractSend to
Oncotarget. 2017 Mar 28;8(13):20558-20571. doi: 10.18632/oncotarget.16137.
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK1, Vandeveer AJ1, Schlom J1, Greiner JW1.
Author information
Abstract
The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a combinatorial benefit in multiple murine tumor models. The murine version of the immunocytokine, NHS-muIL12, consists of an antibody (NHS76) recognizing DNA/DNA-histone complexes, fused with two molecules of murine IL-12 (NHS-muIL12). By its recognition of exposed DNA, NHS-muIL12 targets IL-12 to the necrotic portions of tumors; it has a longer plasma half-life and better antitumor efficacy against murine tumors than recombinant murine IL-12. It is shown here that NHS-muIL12, in an IFN-?â??dependent mechanism, upregulates mPD-L1 expression on mouse tumors, which could be construed as an immunosuppressive action. Yet concurrent therapy with NHS-muIL12 and an anti-PD-L1 antibody resulted in additive/synergistic antitumor effects in PD-L1â??expressing subcutaneously transplanted tumors (MC38, MB49) and in an intravesical bladder tumor model (MB49). Antitumor efficacy correlated with (a) with a higher frequency of tumor antigen-specific splenic CD8+ T cells and (b) enhanced T cell activation over a wide range of NHS-muIL12 concentrations. These findings suggest that combining NHS-muIL12 and an anti-PD-L1 antibody enhances T cell activation and T cell effector functions within the tumor microenvironment, significantly improving overall tumor regression. These results should provide the rationale to examine the combination of these agents in clinical studies.
KEYWORDS:
PD-L1; checkpoint inhibitor; immunocytokine; immunotherapy; interleukin-12
PMID: 28423552 PMCID: PMC5400526 DOI: 10.18632/oncotarget.16137
[Indexed for MEDLINE] Free PMC Article
Share on FacebookShare on TwitterShare on Google+
Images from this publication.See all images (7)Free text
Figure 1Figure 2Figure 3Figure 4Figure 5Figure 6
MeSH terms, Substances
LinkOut - more resources
PubMed Commons home
PubMed Commons
0 comments
How to join PubMed Commons
Supplemental Content
Full text links
Icon for Impact Journals, LLC Icon for PubMed Central
Save items
Add to Favorites
View more options
Similar articles
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
[Clin Cancer Res. 2017]
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
[Oncotarget. 2014]
Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
[Cancer Immunol Res. 2016]
Review The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
[Clin Ther. 2015]
Review Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
[Handb Exp Pharmacol. 2008]
See reviews...
See all...
Related information
Articles frequently viewed together
MedGen
References for this PMC Article
Free in PMC
Recent Activity
ClearTurn Off
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with av...
PubMed
See more...
You are here: NCBI > Literature > PubMedSupport Center
Simple NCBI Directory
GETTING STARTED
NCBI Education
NCBI Help Manual
NCBI Handbook
Training & Tutorials
Submit Data
RESOURCES
Chemicals & Bioassays
Data & Software
DNA & RNA
Domains & Structures
Genes & Expression
Genetics & Medicine
Genomes & Maps
Homology
Literature
Proteins
Sequence Analysis
Taxonomy
Variation
POPULAR
PubMed
Bookshelf
PubMed Central
PubMed Health
BLAST
Nucleotide
Genome
SNP
Gene
Protein
PubChem
FEATURED
Genetic Testing Registry
PubMed Health
GenBank
Reference Sequences
Gene Expression Omnibus
Map Viewer
Human Genome
Mouse Genome
Influenza Virus
Primer-BLAST
Sequence Read Archive
NCBI INFORMATION
About NCBI
Research at NCBI
NCBI News & Blog
NCBI FTP Site
NCBI on Facebook
NCBI on Twitter
NCBI on YouTube
NLM NIH DHHS USA.gov
National Center for Biotechnology Information, U.S. National Library of Medicine
8600 Rockville Pike, Bethesda MD, 20894 USA
Policies and Guidelines | Contact
